E
Evox Therapeutics
Biotech & Life Sciences · Oxford, United Kingdom · Founded 2016
Exosome-based gene editing therapies for neurological diseases MoreLess
Evox Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of exosome therapeutics. Exosomes are tiny vesicles that cells use to communicate with each other, and Evox is leveraging this natural delivery system to create treatments for serious, life-threatening rare diseases. These are conditions that currently have limited treatment options, making Evox's work potentially life-changing for patients and their families.
Evox's business model revolves around its proprietary DeliverEX™ platform, which combines the delivery capabilities of exosomes with targeting technology and advanced biomolecular engineering. This platform is used to develop a pipeline of therapeutics, both internally and in partnership with other companies. By partnering with other firms, Evox can both leverage their expertise and resources, and also provide them with access to its innovative technology.
The company's revenue comes from two main sources. First, from the development and eventual sale of its own therapeutics. Second, from partnerships with other companies who pay to use the DeliverEX™ platform or to co-develop therapeutics.
In summary, Evox Therapeutics is a pioneering biotech firm that's using its unique technology to create treatments for rare diseases. It operates in a niche but important market, and its business model combines internal development with strategic partnerships.
Keywords: Biotechnology, Healthcare, Exosome Therapeutics, Rare Diseases, DeliverEX™ Platform, Biomolecular Engineering, Drug Development, Strategic Partnerships, Life-threatening Diseases, Treatment Options.
Company overview
Evox Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 44
- Open positions
- None listed
- Dealroom signal
- 73.4
- Investment activity
- 1 companies · latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Evox Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2021 | $91M | $365M | Invus · OrbiMed · Cowen Healthcare Investments · Redmile Group | — |
| CONVERTIBLEOther financing | Jun 2020 | $10M | — | Lilly Ventures | — |
| GRANTOther financing | Sep 2019 | $2M | — | Undisclosed | — |
| GRANTOther financing | Mar 2019 | $2M | — | Undisclosed | — |
| SERIES BOther financing | Sep 2018 | $47M | $187M | Cowen Group · Panacea Capital Advisors · Redmile Group · Borealis Ventures | ↗ |
| SERIES AOther financing | May 2016 | Oxford Science Enterprises | — | ||
| SPINOUTOther financing | Jan 2016 | University of Oxford · Oxford University Innovation | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $12M | 0% | −$29M | -241.3% |
| 2025 | $12M | 0% | −$29M | -241.3% |
| 2024 | $12M | 0% | −$29M | -241.3% |
| 2023 | $12M | +28.5% | −$29M | -241.3% |
| 2022 | $9.5M | -70.1% | −$29M | -310.1% |
| 2021 | $32M | +263.6% | −$7.7M | -24.4% |
| 2020 | $8.7M | — | −$12M | -136.4% |
Growth signals
Evox Therapeutics website traffic
Latest recorded traffic for Evox Therapeutics is 5.5K monthly website visits, up 52.8% over the last three months. Evox Therapeutics's team declined 4.3% over the past year.
Comparisons
Evox Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 KinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection |
Macclesfield, United Kingdom | Operational | 26 | $6.9M | $21M |
 WaveBreakSmall-molecule therapeutics for neurodegenerative diseases |
Cambridge, United Kingdom | Operational | |||
 SpyBiotechNovel vaccine platform using protein superglue technology |
Oxford, United Kingdom | Operational | |||
 Caldan TherapeuticsDevelops innovative therapeutics targeting Type 2 Diabetes |
Edinburgh, United Kingdom | Closed | |||
 IkarovecBi-functional gene therapies for chronic eye diseases |
Norwich, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 MedisieveMagnetic blood filtration enhancing gene therapy efficacy. |
London, United Kingdom | Operational | |||
 SansanimaHuman cell-based assays replacing animal testing. |
Sheffield, United Kingdom | Operational |
Capital deployed
Evox Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Evox Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Evox Therapeutics has talent and traffic
team presence
In the news
Latest news about Evox Therapeutics
Recent press, funding announcements, and product moves mentioning Evox Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Evox Therapeutics
An AI-synthesized read of the highest-engagement posts about Evox Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evox Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.